Carmepem

Meropenem trihydrate

Treatment of complicated skin & skin structure infections in adult & ped ≥3 mth; complicated intraabdominal infections in adult & ped; bacterial meningitis in ped ≥3 mth.

Adult 1 g every 8 hr by IV bolus (5-20 mL) over 3-5 min. Skin & skin structure infections 500 mg every 8 hr by IV infusion over 15-30 min. Infections caused by P. aeruginosa 1 g every 8 hr. Intraabdominal infections 1 g every 8 hr by IV infusion for over 15-30 min. Renal impairment CrCl >50 mL/min 500 mg (cSSSI) & 1 g (intraabdominal) every 8 hr, 26-50 mL/min Follow recommended dose every 12 hr, 10-25 mL/min ½ recommended dose every 12 hr, <10 mL/min ½ recommended dose every 24 hr. Ped ≥3 mth w/ normal renal function Complicated skin & skin structure infections 10 mg/kg every 8 hr. Max: 500 mg. Complicated skin & skin structure infections caused by P. aeruginosa 20 mg/kg (or 1 g for ped weighing >50 kg) every 8 hr. Intraabdominal infections 20 mg/kg every 8 hr. Max: 1 g. Meningitis 40 mg/kg every 8 hr. Max: 2 g. IV infusion is to be given over approx 15-30 min. IV bolus inj (5-20 mL) is to be given 3-5 min. Ped <3 mth w/ complicated intraabdominal infections & normal renal function: Infant <32 wk gestational age (GA) & postnatal age (PNA) <2 wk 20 mg/kg every 12 hr. Infant <32 wk GA & PNA ≥2 wk 20 mg every 8 hr. Infant ≥32 wk GA & PNA <2 wk 20 mg/kg every 8 hr. Infant ≥32 wk GA & PNA ≥2 wk 30 mg/kg every 8 hr. IV infusion is to be given over 30 min.

Hypersensitivity to meropenem & β-lactams.

History of sensitivity to multiple allergens; previous hypersensitivity reactions to penicillins, cephalosporins, other β-lactams & other allergens. Discontinue if allergic reaction occurs. Seizure potential in patients w/ CNS disorders (eg, brain lesions or history of seizures) or w/ bacterial meningitis &/or compromised renal function; patients w/ known factors that predispose to convulsive activity. Co-administration w/ valproic acid or divalproex Na is not recommended. Consider C. difficile-associated diarrhea (CDAD) in patients who present w/ diarrhea following antibacterial drug use. Discontinue if CDAD is suspected or confirmed. Prophylactic indication is unlikely & increases the risk of development of drug-resistant bacteria. Overgrowth of nonsusceptible organisms on prolonged use. Periodic assessment of organ system functions including renal, hepatic & hematopoietic during prolonged therapy. Patients on hemodialysis or peritoneal dialysis. Do not operate machinery or motorized vehicles. Renal impairment. Pregnancy & lactation.

Hypersensitivity reactions, seizure potential, CDAD, development of drug-resistant bacteria, overgrowth of nonsusceptible organisms, potential for neuromotor impairment.

Increased plasma conc w/ probenecid. Decreases serum conc of valproic acid or divalproex Na.

Other Beta-Lactams

J01DH02 - meropenem ; Belongs to the class of carbapenems. Used in the systemic treatment of infections.

Rx